Gilead inks deal with Canadian antibody discovery firm AbCellera

05:50 EDT 14 Jun 2019 | Pharmafile

Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera.

The two firms will take part in a cross border collaboration to support the discovery of new therapeutic antibody candidates for infectious diseases.

Under the terms of the agreement AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

read more

Original Article: Gilead inks deal with Canadian antibody discovery firm AbCellera


More From BioPortfolio on "Gilead inks deal with Canadian antibody discovery firm AbCellera"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...